Alimera Sciences Analysis
Alimera Sciences is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Alimera Sciences delisted stock analysis is to determine its intrinsic value, which is an estimate of what Alimera Sciences is worth, separate from its market price. There are two main types of Alimera Sciences' stock analysis: fundamental analysis and technical analysis.
The Alimera Sciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Alimera Sciences is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Alimera Stock trading window is adjusted to America/New York timezone.
Alimera |
Alimera Stock Analysis Notes
About 87.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the 15th of November 2019. Alimera Sciences had 1:15 split on the 15th of November 2019. Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. For more info on Alimera Sciences please contact the company at 678 990 5740 or go to https://alimerasciences.com.Alimera Sciences Investment Alerts
| Alimera Sciences is not yet fully synchronised with the market data | |
| Alimera Sciences has some characteristics of a very speculative penny stock | |
| Alimera Sciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 80.75 M. Net Loss for the year was (20.13 M) with profit before overhead, payroll, taxes, and interest of 52 M. | |
| Alimera Sciences currently holds about 7.86 M in cash with (14.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.12. | |
| Over 87.0% of the company shares are held by institutions such as insurance companies |
Alimera Sciences Upcoming and Recent Events
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Alimera Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 301.29 M.Alimera Profitablity
The company has Profit Margin (PM) of (0.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.Alimera Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alimera Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alimera Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alimera Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jones John Philip over six months ago Acquisition by Jones John Philip of 8750 shares of Alimera Sciences subject to Rule 16b-3 | ||
Morgan Adam over six months ago Disposition of 7000 shares by Morgan Adam of Alimera Sciences at 1.7 subject to Rule 16b-3 | ||
Morgan Adam over six months ago Disposition of 6000 shares by Morgan Adam of Alimera Sciences at 2.1 subject to Rule 16b-3 | ||
Richard Eiswirth over a year ago Acquisition by Richard Eiswirth of 500 shares of Alimera Sciences at 4.437 subject to Rule 16b-3 | ||
Maltz Elliot over a year ago Acquisition by Maltz Elliot of 75000 shares of Alimera Sciences subject to Rule 16b-3 | ||
Wood Todd Michael over a year ago Acquisition by Wood Todd Michael of 125000 shares of Alimera Sciences subject to Rule 16b-3 | ||
John Snisarenko over a year ago Acquisition by John Snisarenko of 50000 shares of Alimera Sciences subject to Rule 16b-3 | ||
Skibsted Russell over a year ago Acquisition by Skibsted Russell of 58000 shares of Alimera Sciences subject to Rule 16b-3 |
Alimera Sciences Outstanding Bonds
Alimera Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alimera Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alimera bonds can be classified according to their maturity, which is the date when Alimera Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ATDBCN 34 13 MAY 41 Corp BondUS01626PAP18 | View | |
| ATDBCN 3625 13 MAY 51 Corp BondUS01626PAQ90 | View | |
| ATDBCN 355 26 JUL 27 Corp BondUS01626PAH91 | View | |
| ATDBCN 295 25 JAN 30 Corp BondUS01626PAM86 | View | |
| ATDBCN 38 25 JAN 50 Corp BondUS01626PAN69 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Alimera Sciences to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Alimera Stock
If you are still planning to invest in Alimera Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alimera Sciences' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |